share_log

Virpax Pharmaceuticals | DEFA14A: Others

Virpax Pharmaceuticals | DEFA14A: Others

Virpax製藥 | DEFA14A:其他
美股SEC公告 ·  07/09 04:38

牛牛AI助理已提取核心訊息

Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into...Show More
Virpax Pharmaceuticals, Inc. has issued a supplement to its definitive proxy statement, detailing significant changes ahead of its 2024 Annual Meeting of Stockholders scheduled for July 29, 2024. The supplement, dated July 5, 2024, follows the company's entry into a Securities Purchase Agreement with an institutional investor, resulting in a $2.5 million financing deal. This transaction prompted a reorganization of the company's Board of Directors, with the resignation of five directors and the appointment of four new ones, including Judy Su, Jatinder Dhaliwal, Katharyn Field, and Gary Herman. Dr. Jeffrey Gudin's resignation as a Class III director led to Gary Herman's appointment in his stead, with Herman now standing for reelection at the upcoming Annual Meeting. The Board has been restructured into three classes, with the current composition being seven directors. The company has also updated its proxy card to reflect the nominee changes and advises stockholders who have already voted and do not wish to change their vote that no further action is required. The proxy materials, including the amended notice, proxy statement, supplement, updated proxy card, and the 2023 Annual Report, are available at www.proxyvote.com.
Virpax藥品公司已發佈補充披露文件,詳細說明了2024年股東年會的重大變化,該股東年會定於2024年7月29日舉行。該補充文件於2024年7月5日發佈,緊隨該公司與機構投資者簽訂一份證券購買協議,交易額爲250萬美元。此項交易促使公司董事會重新組織,五名董事辭職,其中四名新董事被任命,包括Judy Su、Jatinder Dhaliwal、Katharyn Field和Gary Herman。Dr. Jeffrey Gudin作爲三級董事的辭職導致了Gary Herman接替他的任命,現在Herman將在即將舉行的股東年會上競選連任。董事會已分爲三個等級,目前成員爲七名董事。該公司還更新了全權代理卡以反映提名人的變化,並建議已經投票且不希望更改選票的股東無需採取進一步行動。代理材料,包括修訂後的通知書、代理聲明、補充材料、更新的代理卡和2023年年度報告,可在www.proxyvote.com獲取。
Virpax藥品公司已發佈補充披露文件,詳細說明了2024年股東年會的重大變化,該股東年會定於2024年7月29日舉行。該補充文件於2024年7月5日發佈,緊隨該公司與機構投資者簽訂一份證券購買協議,交易額爲250萬美元。此項交易促使公司董事會重新組織,五名董事辭職,其中四名新董事被任命,包括Judy Su、Jatinder Dhaliwal、Katharyn Field和Gary Herman。Dr. Jeffrey Gudin作爲三級董事的辭職導致了Gary Herman接替他的任命,現在Herman將在即將舉行的股東年會上競選連任。董事會已分爲三個等級,目前成員爲七名董事。該公司還更新了全權代理卡以反映提名人的變化,並建議已經投票且不希望更改選票的股東無需採取進一步行動。代理材料,包括修訂後的通知書、代理聲明、補充材料、更新的代理卡和2023年年度報告,可在www.proxyvote.com獲取。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。